In the general news, President Obama attended a meeting on NATO in Estonia to show solidarity against Russia. In the U.S., job growth for August was surprisingly low.
In healthcare business news, the Labor Day holiday was stretched into a full week. the news was slow.
From the FDA, Merck (MRK) received approval for PD-1 blocker Keytruda to treat melanoma. Keryx (KERX) won approval for Ferric Citrate to treat hyperphosphatemia in renal disease, but unexpected warning labels sent shares down. Prana (PRAN) won orphan status for PBT2 to treat Huntington’s Disease. Lastly, Acadia (ACAD) was awarded “Breakthrough” status for Nuplazid to treat Parkinson’s psychosis.